List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
Generative AI is broadening the boundaries of what is possible in drug discovery. In this article, Murat Tunaboylu, CEO and Co-founder of Antiverse, reveals how the zeitgeist technology is enabling scientists to tackle previously undruggable targets like GPCRs and ion channels to deliver patient impact faster.
Metrion Biosciences has introduced a breakthrough NaV1.9 screening assay, aimed at overcoming historical challenges in pain research and advancing the development of non-opioid treatments.
See how the new Shasta™ Single Cell System enabled high-throughput single-cell DNA-seq library preparation to detect tumor-driving mutations.
In this first interview of a two-part series, Andreas Kolleger explores the convergence of knowledge graphs and large language models. As the head of GenAI innovation at Neo4j, Andreas brings a unique cross-industry perspective on how these technologies can enhance life sciences workflows.
11 April 2025 | By Drug Target Review
Our editorial webinars provide free access to expert insights from leading scientists and industry professionals, offering high-quality educational content that serves as a valuable resource. These webinars generate hundreds of leads, providing a straightforward way to engage your target audience. By submitting your company’s logo, you'll receive full access to…
Scientists have identified protein tyrosine phosphatase delta (PTPRD) as a key regulator of liver metabolism, offering a potential new drug target for treating metabolic liver diseases like MASLD and MASH.
New research, led by USC Stem Cell scientists, has identified key genetic barriers to sensory cell regeneration in the ear and eye, paving the way for future drug therapies to restore hearing and vision.
4 April 2025 | By Eurofins Discovery
Join Dr. Francisca Neethling from Eurofins Discovery to explore the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
In this interview with Jose-Manuel Collados, learn how ABB's strategic partnerships and automation technology are improving lab efficiency, enhancing precision and ultimately speeding up the development of life-saving treatments.
28 March 2025 | By Drug Target Review
Join this expert-led webinar to discover how lab automation and AI are transforming early preclinical research. Learn how cutting-edge technologies are reshaping lab workflows, improving reproducibility, and fast-tracking drug development from discovery to preclinical validation.
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
The era of precision medicine demands more rigorous biomarker validation methods. While ELISA has long been the gold standard, advanced technologies such as LC-MS/MS and Meso Scale Discovery (MSD) offer superior precision, sensitivity and efficiency. Here, Prasad Lakshmanan Selvaraj, Director of Technical Review at Sannova, explains that by embracing these…
Sphere Fluidics have developed the Cyto-Mine® Chroma platform, which provides multiplexing and greater assay flexibility, reducing timelines and cost.
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
